Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $65 price target.
November 08, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Bicycle Therapeutics and maintained a $65 price target, which could positively influence the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Cantor Fitzgerald's reiteration of an Overweight rating and a $65 price target for Bicycle Therapeutics indicates a positive outlook for the company, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100